Pharmaceutical & Drug Policy
Incorporating information on therapeutic alternatives into the IRA prescription drug negotiations
The American Recovery and Reinvestment Act of 2009 invested $1.1 billion in federal initiatives to begin the important and necessary work of comparative effectiveness research (CER), a key building block in health care reform. However, whether CER can fulfill expectations of better quality, outcomes and value in health care will depend on how it is implemented.
A forum hosted by the Engelberg Center for Health Care Reform and The Hamilton Project addressed many of the key questions surrounding CER and featured remarks from Sen. Max Baucus (D-Mont.) and Office of Management and Budget Director Peter Orszag. Three discussion papers released at the event focus on how research questions should be prioritized, what methods and data infrastructure are needed for CER, and how CER findings can be used to improve clinical and health policy decisions. A series of distinguished panels discussed the papers’ findings.
Participants took questions after each panel.
Agenda
-
June 9
-
Getting Our Money's Worth from Patient-Centered Health Research
DPODr. Peter Orszag Director, Congressional Budget Office -
Comparative Effectiveness Research: What It Is, What It's Not and Why We Need More
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke UniversityDLDavid Lansky President and CEO, Pacific Business Group on Health -
Welcome
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke University -
The Future of Comparative Effectiveness Research in the United States
MBMax Baucus Former U.S. Ambassador to China (2014-2017), Former U.S. Senator, Montana -
Introductory Remarks
Robert E. Rubin Former U.S. Treasury Secretary, Co-Chair Emeritus - Council on Foreign Relations -
Setting Priorities for Comparative Effectiveness Research (Discussion Paper 1)
PAGPresenter: Alan Garber Director, Center for Primary Care and Outcomes Research, Stanford School of MedicinePDMPresenter: David Meltzer Associate Professor, University of Chicago School of Medicine
Mark Miller Executive Director - Medicare Payment Advisory CommitteeENElizabeth Nabel Director, National Heart, Lung, and Blood InstituteHSHarold Sox Past President, American College of Physicians -
Strategies to Improve Comparative Effectiveness Research Methods and Data Infrastructure (Discussion Paper 2)
RMCRobert M. Califf Duke Translational Medicine Institute
Joshua Ofman Senior Vice President, Global Value Access & Policy - AmgenSSSebastian Schneeweiss Harvard Medical School and Brigham and Women’s HospitalESEllen Sigal Chairperson and Founder - Friends of Cancer Research -
From Better Evidence to Better Care: Using Comparative Effectiveness Research to Guide Practice and Policy (Discussion Paper 3)
PSPPresenter: Steven Pearson Director, Institute for Clinical and Economic ReviewSFSteven Findlay Senior Health Policy Analyst, Consumers Union
MBMarc Berger Vice President, Global Health Outcomes, Eli Lilly & Co.SNSam Nussbaum Executive Vice President, Clinical Health Policy and Chief Medical Officer - WellPoint, Inc. -
Closing Remarks
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke University
-
